Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
March 06 2023 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, will release financial results for
the quarter and year ended December 31, 2022, after the market
close on Monday, March 20, 2023. John Aballi, Exagen’s President
and Chief Executive Officer, and Kamal Adawi, Chief Financial
Officer, will host a conference call to review the Company’s
results at 4:30 PM ET (1:30 PM PT).
Interested parties may access the conference call by dialing
(201) 389-0918 (U.S.) or (877) 407-0890 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
investors.exagen.com.
A replay of the conference call will be available until Monday,
April 3, 2023, at 11:59 PM ET (8:59 PM PT). Interested parties may
access the replay of the conference call by dialing (201) 612-7415
(U.S.) or (877) 660-6853 (international) using passcode 13736103.
Additionally, a recording of the webcast will be available using
the link on the Exagen investor relations website approximately one
hour after the call concludes.
About Exagen Inc.
Exagen is a leading provider of autoimmune diagnostic,
prognostic, and monitoring testing solutions. Exagen is a
patient focused, discovery driven organization built on the success
of AVISE® testing and is investing in its product pipeline to
support patients throughout their autoimmune diagnosis and
treatment journeys. The goal at Exagen is to assist patients,
physicians, and payors by enabling precision
medicine. Exagen is located in San Diego County.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
CONTACTS:
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024